GoodRx Q4 Revenue Flat at $196 M, 300K Customer Decline Raises Concerns
GoodRx posted flat Q4 revenue of $196 million but lost 300,000 customers, ending with 5.4 million users, and missed EPS estimates. Analysts forecast a 2.7% year-over-year revenue decline in the next quarter and maintain a $4.56 average price target as the stock fell 9.1% last month.
1. Q4 Financial Results
GoodRx reported Q4 revenue of $196 million, unchanged year-over-year, while missing analysts’ EPS projections. The company lost 300,000 customers, concluding the quarter with 5.4 million active users.
2. Upcoming Quarter Expectations
Analysts project a 2.7% year-over-year revenue decline for the upcoming quarter, reflecting slowed growth compared to the flat Q4 performance. Coverage has remained steady over the past month, indicating confidence in current estimates.
3. Peer Performance Comparison
Tandem Diabetes delivered 15% year-over-year revenue growth and beat expectations by 4.9%, trading up 32.7% post-results. Hims & Hers Health posted 28.4% revenue growth in line with consensus, highlighting sector disparities.
4. Stock Trend and Analyst Targets
Healthcare tech stocks averaged a 3.5% decline last month, while GoodRx shares fell 9.1%. The average analyst price target stands at $4.56 versus the current $2.29 share price, underscoring skepticism on near-term recovery.